A drug maker that moved its research division from California to Chicago early in the COVID-19 pandemic is continuing to invest in its office and lab space footprints in Chicago’s Fulton Market District, which is attracting a lot of traction in the biotech industry.
Xeris Biopharma Holdings has signed a 13-year-lease for about 87,000 square feet (8,082 square meters) at 1375 W. Fulton St., the company confirmed, where it will serve as the anchor tenant. The 14-story buildout is being developed by Trammell Crow and currently houses lab space for several life sciences companies, strengthening the quality of housing for the biotech market in Chicago. Tenants include neurological disorder research firm Vanqua Bio, diagnostic testing company Talis Biomedical and gene therapy product company Charles River Laboratories, among others.
Xeris’ existing space in the city already includes a 40,000-square-foot (3,716-square-meter) headquarters at 180 N. LaSalle St. and an 11,000-square-foot (1,021-square-meter) research lab at 1375 W. Fulton.
Trammell Crow also developed a lab-focused building at nearby 400 N. Aberdeen St.—dubbed Fulton Labs—while Chicago developer Mark Goodman is planning another 16-story life sciences-focused building at 400 N. Elizabeth St. in the former meatpacking neighborhood.
For more on this story, go to Crain’s.